Boardroom Turmoil Erupts at Novo Nordisk

Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent waters as a significant governance conflict unfolds. The company’s shares, already experiencing downward pressure, now face additional uncertainty from an escalating boardroom power struggle that leaves minority shareholders with limited influence.

Today’s extraordinary general meeting will determine the reinstatement of former CEO Lars Rebien Sorensen as Chairman—a decision whose outcome appears predetermined. The Novo Nordisk Foundation, controlling 77% of voting rights, is positioned to enforce its will regardless of opposition from other stakeholders. This development raises crucial questions about the implications for the company’s already struggling stock performance.

The current leadership crisis stems from deep divisions within Read more...